Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy with Durvalumab +/- Monalizumab or Oleclumab in NSCLC (ARCHON-1)
NCT03801902Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2019
- Primary completion
- Oct 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of monalizumab and oleclumab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by National Cancer Institute. Primary endpoints: Number of Participants Experiencing a Safety Event and Number of Participants Experiencing a Safety Event with Add-on. Started Oct 2019; status: completed.
02
Drugs
monalizumaboleclumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03801902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03801902.